Revolution Medicines, INC Form 4 insider transactions
NASDAQ
Director Barbara Weber of Revolution Medicines, Inc. executed a sale of common stock on October 8, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Jack Anders, CFO of Revolution Medicines, sold 2,244 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,715 shares of common stock on September 16, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,331 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,665 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold 1,454 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold shares of common stock on September 13, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Director Barbara Weber of Revolution Medicines, Inc. reports selling 1,808 shares of common stock on August 21, 2024.
NASDAQ
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 16,667 shares of common stock at an average price of $42.9825, while also exercising options to acquire the same number of shares at $4.09.
NASDAQ
Frank Clyburn, a director at Revolution Medicines, acquired shares and options in the company on August 5, 2024.
NASDAQ
Mark A. Goldsmith, CEO of Revolution Medicines, exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Revolution Medicines CEO Mark Goldsmith Executes Stock Option and Sells Shares Under 10b5-1 Plan
Mark Goldsmith, CEO of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold 2,399 shares of common stock at $40.83 per share on July 9, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Revolution Medicines Director Sushil Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan
Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on July 9, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Elizabeth M. Anderson, a director of Revolution Medicines, Inc., files an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Flavia Borellini, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Barbara Weber, a director at Revolution Medicines, files an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Lorence H. Kim, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units (RSUs) and stock option awards granted on June 20, 2024.
NASDAQ
Alexis Borisy, a director at Revolution Medicines, filed an amended SEC Form 4 to correct previously reported amounts for restricted stock units (RSUs) and stock options granted on June 20, 2024.
NASDAQ
Sushil Patel, a director at Revolution Medicines, filed an amended SEC Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Sandra Horning, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold 2,000 shares of common stock at an average price of $38.4698 on June 26, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Revolution Medicines Executive Stephen Michael Kelsey Reports Stock Option Exercises and Sales
Stephen Michael Kelsey, a key executive at Revolution Medicines, executed stock option exercises and subsequent sales of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Director Sandra Horning reports acquisition of Revolution Medicines stock and options.
NASDAQ
Director Sushil Patel acquired 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Form 4: Revolution Medicines Director, Alexis Borisy, Reports Acquisition of Shares and Stock Options
Director Alexis Borisy reports acquiring 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Form 4: Revolution Medicines Director Lorence H. Kim Reports Acquisition of Shares and Stock Options
Director Lorence H. Kim reports acquisition of 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Director Barbara Weber reports acquiring 4,800 shares of common stock and stock options for 16,700 shares in Revolution Medicines.